NeutralLOW severityHealthcare & Pharma65d ago

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone — $GLUE one-month chart
$GLUE daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about GLUE. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · monte rosaEvent risk Low

Nothing reported about monte rosa across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 53% a year
Now $9.07Week $8.39–$9.75 (±7.5%)Month $7.68–$10.46 (±15.3%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
  • How the stock is trading: $GLUE -0.98% in the latest session.
  • Timing: It came out on a weekend, so the change shown is Friday's and Monday's open is the first chance to trade on it. Market holidays are not detected.
Amount$50 million

Where the stock stands

Monte Rosa Therapeutics ($GLUE) slipped 0.98% to $9.07 in the latest session. Over the past month it is down 14.9%. It now sits 65% under the 52-week high of $25.77 and 2.7% above the year's low of $8.83, close to the bottom of its range. The year's high was 2.9 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 5, 2026), $GLUE earned $3.1M over the quarter to Sep 30, 2026. Operations used $122.5M of cash over the nine months to Sep 30, 2026 — about $13.7M a month — against $45.2M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $201.5M against $45.2M of cash on Sep 30, 2026. Its most recent filings before this story: 8-K on Sep 8, 2026, 10-Q on Aug 6, 2026, 8-K on Aug 6, 2026. Figures are as filed with the SEC; the $GLUE page has the full statements.

How much coverage it is getting

This story is more than a month old. Since then Wook has filed 2 newer stories on Monte Rosa Therapeutics in the last 30 days, 1 of them this week. By their wording, 1 read bullish, 1 neutral and 0 bearish.

The bigger picture

In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

For the company's side of it, read its latest SEC filings on the $GLUE page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $GLUE: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Yahoo Finance published this on September 13, 2026. $GLUE has moved -34.75% ($13.90 to $9.07). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Yahoo Finance. Wook of Wall Street is an independent research tool and is not affiliated with Yahoo Finance. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy